MA34838B1 - Composés de pyrazole en tant qu'antagonistes de crth2 - Google Patents

Composés de pyrazole en tant qu'antagonistes de crth2

Info

Publication number
MA34838B1
MA34838B1 MA36130A MA36130A MA34838B1 MA 34838 B1 MA34838 B1 MA 34838B1 MA 36130 A MA36130 A MA 36130A MA 36130 A MA36130 A MA 36130A MA 34838 B1 MA34838 B1 MA 34838B1
Authority
MA
Morocco
Prior art keywords
compounds
pyrazole compounds
crth2 antagonists
pharmaceutical preparations
pyrazole
Prior art date
Application number
MA36130A
Other languages
English (en)
Inventor
Ralf Anderskewitz
Domnic Martyres
Thorsten Oost
Wolfgang Rist
Peter Seither
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43799503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34838(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA34838B1 publication Critical patent/MA34838B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composés de pyrazole représentés par la formule (1a) ou (1b) et sels pharmaceutiquement acceptables de ces composés, formules dans lesquelles Ra, Rb, Rc, Rd, Y1, y2, y3, y4, y5, Z, R1, R2, n et R3 sont comme définis dans les spécifications et les revendications, leurs utilisations comme médicaments, des préparations pharmaceutiques contenant lesdits composés et des préparations pharmaceutiques des dits composés combinées à un ou plusieurs principes actifs. Ces composés possèdent une activité antagoniste à CTRH2.
MA36130A 2011-01-24 2012-01-20 Composés de pyrazole en tant qu'antagonistes de crth2 MA34838B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11151876 2011-01-24
PCT/EP2012/050830 WO2012101043A1 (fr) 2011-01-24 2012-01-20 Composés de pyrazole en tant qu'antagonistes de crth2

Publications (1)

Publication Number Publication Date
MA34838B1 true MA34838B1 (fr) 2014-01-02

Family

ID=43799503

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36130A MA34838B1 (fr) 2011-01-24 2012-01-20 Composés de pyrazole en tant qu'antagonistes de crth2

Country Status (35)

Country Link
US (1) US8759386B2 (fr)
EP (1) EP2668181B1 (fr)
JP (1) JP5695216B2 (fr)
KR (2) KR102251939B1 (fr)
CN (4) CN104961732B (fr)
AP (1) AP3343A (fr)
AR (1) AR084916A1 (fr)
AU (1) AU2012210718B2 (fr)
BR (1) BR112013017570B1 (fr)
CA (1) CA2825458C (fr)
CL (1) CL2013001945A1 (fr)
CO (1) CO6801731A2 (fr)
CY (1) CY1116012T1 (fr)
DK (1) DK2668181T3 (fr)
EA (1) EA022559B1 (fr)
EC (1) ECSP13012832A (fr)
ES (1) ES2529452T3 (fr)
GE (1) GEP20156332B (fr)
HR (1) HRP20150069T1 (fr)
IL (1) IL226920A (fr)
MA (1) MA34838B1 (fr)
MX (1) MX342830B (fr)
MY (1) MY163012A (fr)
PE (1) PE20140860A1 (fr)
PH (2) PH12013501356A1 (fr)
PL (1) PL2668181T3 (fr)
PT (1) PT2668181E (fr)
RS (1) RS53785B1 (fr)
SG (1) SG192096A1 (fr)
SI (1) SI2668181T1 (fr)
TN (1) TN2013000280A1 (fr)
TW (1) TWI527809B (fr)
UA (1) UA109696C2 (fr)
UY (1) UY33873A (fr)
WO (1) WO2012101043A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527809B (zh) * 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為ｃｒｔｈ２拮抗劑之吡唑化合物
US9206164B2 (en) * 2011-03-25 2015-12-08 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
WO2014079803A1 (fr) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Composés bicyclosubstitués de pyrazole pour le traitement de l'alopécie
US20140148484A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
EP3768245A4 (fr) * 2018-03-23 2023-10-18 Palatin Technologies, Inc. Formulations peptidiques spécifiques du récepteur de la mélanocortine et procédés d'administration spécifiques au tractus gastro-intestinal
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
KR102791027B1 (ko) * 2023-07-03 2025-04-07 주식회사 이노보테라퓨틱스 신규한 피라졸 유도체 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
ES2225252T3 (es) * 1999-11-10 2005-03-16 Takeda Chemical Industries, Ltd. Compuestos n-heterociclicos de 5 miembros con actividad hipoglucemica e hipolipidemica.
ES2257616T3 (es) 2003-04-25 2006-08-01 Actimis Pharmaceuticals, Inc. Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
ATE386725T1 (de) 2003-10-24 2008-03-15 Glaxo Group Ltd Heterocyclylverbindungen
KR20070092297A (ko) * 2004-12-21 2007-09-12 데브젠 엔브이 Ｋｖ4 이온 채널 활성을 갖는 화합물
JP4950542B2 (ja) * 2006-04-07 2012-06-13 岩手東芝エレクトロニクス株式会社 固体撮像装置およびその製造方法
US20090149524A1 (en) 2006-06-06 2009-06-11 Paul John Beswick N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration
BRPI0718672A2 (pt) * 2006-11-27 2013-11-26 Pfizer Prod Inc Análogos de pirazol
ES2383249T3 (es) 2007-09-25 2012-06-19 Actimis Pharmaceuticals, Inc. Alquiltiopirimidinas como antagonistas de CRTH2
CL2008002827A1 (es) 2007-09-25 2009-11-27 Actimis Pharmaceuticals Inc Compuestos derivados de 2-s-bencil pirimidina, antagonistas del receptor crth2; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades alergicas mediadas por eosinofilos y basofilos, tales como asma, rinitis alergica, dermatitis atopica, conjuntivitis alergica, sinusitis y psoriasis, entre otras
JP2011088826A (ja) * 2008-01-31 2011-05-06 Astellas Pharma Inc 芳香族カルボン酸化合物
CA2729292C (fr) * 2008-07-03 2013-09-03 Amira Pharmaceuticals, Inc. Sulfide de phenoxyphenyl, sulfinyle et sulfonyle antagonistes des recepteurs d2 de la prostaglandine
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010057118A2 (fr) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
US20120129820A1 (en) * 2009-02-09 2012-05-24 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
KR101906791B1 (ko) * 2010-01-27 2018-10-11 베링거 인겔하임 인터내셔날 게엠베하 Ｃｒｔｈ２ 길항제로서의 피라졸 화합물
WO2012013567A1 (fr) * 2010-07-28 2012-02-02 Boehringer Ingelheim International Gmbh Composition pharmaceutique pour le traitement de maladies respiratoires et inflammatoires
TWI527809B (zh) * 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為ｃｒｔｈ２拮抗劑之吡唑化合物

Also Published As

Publication number Publication date
HK1186183A1 (en) 2014-03-07
CN103339125A (zh) 2013-10-02
KR20140005931A (ko) 2014-01-15
CN104628705A (zh) 2015-05-20
CN103339125B (zh) 2015-07-15
JP5695216B2 (ja) 2015-04-01
EP2668181A1 (fr) 2013-12-04
CN104961732A (zh) 2015-10-07
BR112013017570B1 (pt) 2022-01-11
RS53785B1 (sr) 2015-06-30
US8759386B2 (en) 2014-06-24
HRP20150069T1 (hr) 2015-02-27
CN107011332B (zh) 2020-03-13
MX2013008082A (es) 2013-09-13
ECSP13012832A (es) 2013-09-30
HK1210467A1 (en) 2016-04-22
KR101923365B1 (ko) 2018-11-30
IL226920A (en) 2016-11-30
HK1215247A1 (zh) 2016-08-19
CN107011332A (zh) 2017-08-04
CL2013001945A1 (es) 2013-10-25
EP2668181B1 (fr) 2014-11-05
GEP20156332B (en) 2015-07-27
UY33873A (es) 2012-07-31
TN2013000280A1 (en) 2014-11-10
KR20180129962A (ko) 2018-12-05
SI2668181T1 (sl) 2015-02-27
AR084916A1 (es) 2013-07-10
TW201245184A (en) 2012-11-16
SG192096A1 (en) 2013-08-30
AP2013006942A0 (en) 2013-06-30
AP3343A (en) 2015-07-31
UA109696C2 (xx) 2015-09-25
CO6801731A2 (es) 2013-11-29
CN104628705B (zh) 2017-04-12
PH12018501531A1 (en) 2019-04-08
EA022559B1 (ru) 2016-01-29
CY1116012T1 (el) 2017-01-25
CA2825458A1 (fr) 2012-08-02
EA201300857A1 (ru) 2013-12-30
CN104961732B (zh) 2017-07-11
PT2668181E (pt) 2015-02-05
PH12013501356A1 (en) 2013-09-02
AU2012210718B2 (en) 2016-06-02
JP2014502986A (ja) 2014-02-06
CA2825458C (fr) 2021-01-26
MY163012A (en) 2017-07-31
PL2668181T3 (pl) 2015-04-30
BR112013017570A2 (pt) 2016-10-18
PE20140860A1 (es) 2014-07-20
NZ611695A (en) 2015-04-24
WO2012101043A1 (fr) 2012-08-02
TWI527809B (zh) 2016-04-01
DK2668181T3 (da) 2015-01-19
MX342830B (es) 2016-10-14
ES2529452T3 (es) 2015-02-20
KR102251939B1 (ko) 2021-05-14
US20130023576A1 (en) 2013-01-24
AU2012210718A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
AR068768A1 (es) Derivados de tetrahidroquinolina para tratar trastornos por estres post - traumatico
MA34727B1 (fr) Imidazolylimidazoles condensés utilisés comme composés antiviraux
PH12018501531A1 (en) Pyrazole compounds as crth2 antagonists
BR112015021791A2 (pt) lipídios e composições de lipídios para a liberação de agentes ativos
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
UA112317C2 (uk) Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину
NO20082269L (no) Nye piperaziner som antimalariamidler
MY160036A (en) Pyrazole compounds as crth2 antagonists
MA35941B1 (fr) Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA38854A1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
CY1111102T1 (el) 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
MA44965B1 (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
JO3029B1 (ar) مشتقات مبتكرة مضادة للفطريات ل 5 ، 6 - ثاني هيدرو - 4- [(ثاني فلورو اثيل) فينيل] -4 H - بيرولو [2،1 -a ] [1،4] بينزوديازيبين و 4- ( ثاني فلورو اثيل ) فينيل - 6 H - بيرولو [2،1 -a ] [1،4] بينزوديازيبين
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques
BR112013028197A2 (pt) compostos de benzofurano-piperidina
EP2842938A4 (fr) Nouveaux dérivés de bêta-alanine, leurs sels pharmaceutiquement acceptables et composition pharmaceutique les comprenant en tant qu'ingrédient actif
MA33055B1 (fr) Nouvelle combinaison de principes actifs contenant un anti-inflammatoire non steroidien et un derive de colchicoside
MA37741B1 (fr) Dérivés de benzimidazole-proline
MA39149B1 (fr) Analogues de cortistatine et synthèses et utilisations associées